V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008058 | 240004959 | 1.58 | 58.2 | Palliative (P) | 2014-05-10 | 2014-05-10 | Midostaurin | 01 | N | 240035554 | AML17 TRIAL |
| 240008059 | 240004959 | null | 71.5 | Curative (C) | 2017-05-18 | 2017-06-06 | PMitCEBO-R | N | N | 240035554 | CYCLOPHOSPHAMIDE |
| 240008060 | 240004959 | null | 78.6 | Palliative (P) | 2018-02-18 | 2018-02-22 | Doxorubicin + Olaratumab | null | N | 240035554 | CISPLATIN + DOXORUBICIN |
| 240008061 | 240004960 | 1.67 | 79.5 | Palliative (P) | null | 2014-12-08 | ESHAP | N | N | 240035569 | NORDIC |
| 240008062 | 240004961 | null | 63.9 | Palliative (P) | 2014-09-22 | 2014-10-11 | Cisplatin + Topotecan | null | N | 240035574 | CISPLATIN + ETOPOSIDE |
| 240008063 | 240004961 | 1.72 | 0 | Curative (C) | 2017-07-27 | 2017-08-09 | R CODOX-M/ R IVAC | N | N | 240035574 | TRIPLE INTRATHECAL |
| 240008064 | 240004961 | 1.71 | 59 | Curative (C) | 2015-03-18 | 2015-03-25 | PACLITAXEL | 02 | N | 240035574 | CISPLATIN + PACLITAXEL |
| 240008065 | 240014951 | 1.58 | 53.8 | Palliative (P) | 2014-01-23 | 2014-02-02 | Cisplatin + Etoposide (3 day) | N | N | 240035583 | FLAG + IDARUBICIN |
| 240008066 | 240014951 | 1.71 | 49.2 | Curative (C) | 2014-03-04 | 2014-03-08 | BEP 3 day | 02 | N | 240035583 | FLUDARABINE |
| 240008067 | 240014951 | 1.65 | null | Disease modification (D) | null | 2017-09-14 | ABVD | N | N | 240035583 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240008068 | 240004962 | 1.5 | 66.9 | Curative (C) | 2014-09-09 | 2014-10-19 | IVAC | 1 | Y | 240035590 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008069 | 240004963 | null | 80 | Adjuvant (A) | 2014-12-18 | 2015-01-01 | Bortezomib +/- Dexamethasone | N | N | 240035591 | FCR |
| 240008070 | 240004964 | 1.75 | 0 | Disease modification (D) | 2013-08-18 | 2013-09-03 | FLAG | N | N | 240035596 | CVD R |
| 240008071 | 240010748 | null | 60 | Palliative (P) | 2016-05-27 | 2016-05-27 | Cisplatin + Etoposide (3 day) | N | N | 240035597 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240008072 | 240004965 | 1.61 | null | Palliative (P) | 2016-02-21 | 2016-03-07 | GEMCITABINE + VINORELBINE | 02 | N | 240035601 | IVAC |
| 240008073 | 240004965 | 1.6 | 63.3 | Palliative (P) | 2017-11-17 | 2017-11-17 | CARBOPLATIN + FLUOROURACIL | 2 | N | 240035601 | CISPLATIN + TOPOTECAN |
| 240008074 | 240004966 | 1.65 | 86 | Curative (C) | 2016-10-11 | 2016-10-11 | REMODLB TRIAL | null | null | 240035608 | AML19 TRIAL |
| 240008075 | 240004967 | 1.55 | 69 | Curative (C) | 2015-02-18 | 2015-02-18 | Cisplatin + Etoposide (3 day) | 2 | null | 240035613 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 240008076 | 240004968 | null | 45.3 | Curative (C) | 2015-07-05 | 2015-07-05 | NHL 2003 Gp B COP | 02 | N | 240000071 | GEMCARBO |
| 240008077 | 240004968 | 1.75 | 65.2 | Curative (C) | 2017-07-16 | 2017-07-20 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 240000071 | ALEMTUZUMAB |
| 240008078 | 240004969 | 1.53 | 81.2 | Curative (C) | 2016-07-04 | 2016-07-04 | CISPLATIN + FLUOROURACIL | 2 | N | 240000078 | CAV |
| 240008079 | 240004970 | 1.71 | 85.5 | Palliative (P) | null | 2015-03-22 | Fluorouracil+Mitomycin+RT (Bladder) | 1 | null | 240000098 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008080 | 240010751 | null | 79 | Neo-adjuvant (N) | 2015-12-16 | 2015-12-16 | Cisplatin + Etoposide + RT | N | null | 240000176 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240008081 | 240004971 | 1.73 | 53 | Palliative (P) | null | 2014-05-05 | R-GEM-P | N | Y | 240000256 | CYTARABINE HD + METHOTREXATE HD |
| 240008082 | 240004972 | 1.6 | 62.4 | Palliative (P) | 2014-11-28 | 2014-11-28 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 02 | N | 240000282 | FLUOROURACIL + MITOMYCIN + RT |
| 240008083 | 240010752 | 1.61 | 65.8 | Curative (C) | 2015-11-29 | 2015-11-30 | Cisplatin + Topotecan | N | N | 240000290 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240008084 | 240004973 | 1.72 | 62.2 | Adjuvant (A) | 2014-10-08 | 2014-10-24 | Bortezomib + Cyclophos + Dex | N | N | 240000361 | FLAG |
| 240008085 | 240004973 | 1.58 | 0 | Disease modification (D) | null | 2016-01-30 | Cisplatin + Etoposide (3 day) | null | null | 240000361 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008086 | 240004973 | null | 58 | Curative (C) | 2017-12-09 | 2017-12-14 | IDELALISIB + RITUXIMAB | null | null | 240000361 | CYCLOPHOSPHAMIDE |
| 240008087 | 240014952 | 1.82 | 0 | Disease modification (D) | 2017-10-14 | 2017-11-06 | Methotrexate intrathecal | N | N | 240000435 | BRENTUXIMAB |
| 240008088 | 240004974 | 1.68 | 62.9 | Curative (C) | 2015-08-27 | 2015-09-12 | Methotrexate intrathecal | 2 | null | 240000442 | ABVD |
| 240008089 | 240004974 | 1.81 | 72.1 | Palliative (P) | 2017-05-21 | 2017-05-25 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | null | 240000442 | NORDIC |
| 240008090 | 240004974 | null | 76 | null | 2018-02-06 | 2018-02-07 | DA-EPOCH-R | null | N | 240000442 | FCR |
| 240008091 | 240004974 | 1.77 | null | Disease modification (D) | 2016-12-24 | 2017-01-06 | Cytarabine Low Dose | N | N | 240000442 | PILOT TRIAL |
| 240008092 | 240004975 | 1.8 | 0 | Not known (9) | 2015-05-13 | 2015-05-22 | VEDex | N | N | 240000542 | R-EPOCH |
| 240008093 | 240004976 | 1.72 | null | Disease modification (D) | 2014-10-03 | 2014-10-16 | DHAP - R | N | N | 240000560 | FLAG + IDARUBICIN |
| 240008094 | 240004976 | 1.48 | 69.4 | Palliative (P) | 2016-02-05 | 2016-02-14 | CARBOPLATIN + RT | 02 | null | 240000560 | CAPECITABINE + OXALIPLATIN |
| 240008095 | 240004977 | 1.68 | 67.4 | Curative (C) | 2016-08-30 | 2016-09-03 | ABVD | Y | N | 240000583 | CISPLATIN + FLUOROURACIL + RT |
| 240008096 | 240004978 | 1.81 | null | Palliative (P) | 2017-11-17 | 2017-11-20 | Cytarabine Low Dose | N | N | 240000652 | CYTARABINE |
| 240008097 | 240004979 | 0 | 60.8 | Disease modification (D) | 2016-04-08 | 2016-04-23 | R CODOX M | N | N | 240000660 | CHOP-R + CYTARABINE HIGH DOSE |
| 240008098 | 240004979 | 0 | 116.9 | Palliative (P) | 2018-04-01 | 2018-04-02 | PEMBROLIZUMAB | 02 | N | 240000660 | CISPLATIN + FLUOROURACIL |
| 240008099 | 240004980 | 1.68 | 80 | Curative (C) | null | 2018-08-27 | Cisplatin + Etoposide (3 day) | N | Y | 240000743 | CLADRIBINE |
| 240008100 | 240004981 | 1.69 | 70.4 | Curative (C) | 2018-03-04 | 2018-03-06 | TCH (21 day Trastuzumab) Maint | 2 | Y | 240000791 | CISPLATIN + FLUOROURACIL + RT |
| 240008101 | 240004981 | 1.7 | 86.8 | Palliative (P) | 2015-09-13 | 2015-09-14 | Docetaxel + Gemcitabine with GCSF | 02 | N | 240000791 | CYTARABINE |
| 240008102 | 240004982 | 1.66 | 77.6 | null | null | 2017-07-05 | AML 19 TRIAL | 02 | N | 240000847 | ABVD |
| 240008103 | 240004982 | 1.53 | null | null | 2017-03-11 | 2017-03-11 | Cyclophosphamide oral | Y | N | 240000847 | FCR |
| 240008104 | 240004982 | 1.77 | 71.6 | Palliative (P) | 2013-12-13 | 2013-12-18 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | null | 240000847 | METHOTREXATE INTRATHECAL |
| 240008105 | 240004982 | null | 69.7 | Palliative (P) | 2013-10-10 | 2013-10-31 | AML17 TRIAL | null | null | 240000847 | CISPLATIN + ETOPOSIDE |
| 240008106 | 240004983 | 1.62 | 64.4 | Curative (C) | 2018-02-09 | 2018-02-27 | BEVACIZUMAB + CARBO + DOCETAXEL | N | N | 240001067 | CISPLATIN + TOPOTECAN |
| 240008107 | 240004984 | 1.63 | 87.8 | Curative (C) | 2017-02-18 | 2017-03-07 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 240001087 | ABVD |